Overview

Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare overall survival rates of colorectal cancer patients with multi-organ metastases with an indication for first line systemic treatment randomized for treatment with combination chemotherapy or treatment with combination chemotherapy and additional maximal tumor debulking including surgical tumor resection, RFA, (DEBIRI-)TACE and SBRT, depending on best clinical judgement according to a standardized treatment algorithm. Our hypothesis is that maximal tumor debulking in addition to systemic treatment with chemotherapy and biologicals will provide an improvement in progression free and overall survival in this patient group.
Phase:
N/A
Details
Lead Sponsor:
Radboud University
VU University Medical Center
Collaborator:
Erasmus Medical Center
Treatments:
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin